Announcement PDF Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Avecho Biotechnology Limited ABN 32 056 482 403 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Gregory Collier Date of last notice 27 May 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Beacon Super Fund Pty Ltd <Beacon Super Fund A/c> Gregory Collier is a Director of Beacon Super Fund Pty Ltd and a beneficiary of the fund. Barwon Biotechnology Pty Ltd Gregory Collier is a Director and Shareholder of Barwon Biotechnology Pty Ltd. Date of change 6 May 2026 and 10 May 2026 Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held prior to change Indirect Beacon Super Fund Pty Ltd <Beacon Super Fund A/c> 1. 4,000,000 Fully Paid Ordinary Shares (AVE) 2. 3,000,000 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Barwon Biotechnology Pty Ltd 1. 5,833,333 Fully Paid Ordinary Shares (AVE) 2. 8,749,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) 3. 6,338,595 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Class Quoted options exercisable at $0.012 each expiring on 10 May 2026 (AVEOA); and Fully paid ordinary shares Number acquired 800,000 fully paid ordinary shares Number disposed 800,000 Quoted Options exercised. 10,949,000 Quoted Options expired unexercised. Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation $0.012 per option exercised No. of securities held after change Indirect Beacon Super Fund Pty Ltd <Beacon Super Fund A/c> 1. 4,800,000 Fully Paid Ordinary Shares (AVE) Barwon Biotechnology Pty Ltd 1. 5,833,333 Fully Paid Ordinary Shares (AVE) 2. 6,338,595 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Issue of 800,000 ordinary shares on exercise of 800,000 Quoted Options. Expiry of 10,949,999 Quoted Options unexercised. Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? N/A If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Avecho Biotechnology Limited ABN 32 056 482 403 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Matthew Patrick McNamara Date of last notice 27 May 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Indirect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. PELEHJ145 PTY LTD <M&L MCNAMARA SF A/C> Pelehj145 Pty Ltd <M&L McNamara Super Fund>Mr McNamara is a director and shareholder of the entity. He is also a beneficiary of the super fund. Pelehj145 Pty Ltd <M&L McNamara Super Fund> Mr McNamara is a director and shareholder of the entity. He is also a beneficiary of the super fund. Date of change 10 May 2026 No. of securities held prior to change Indirect PELEHJ145 PTY LTD <M & L MCNAMARA SFA/C> 1. 1,666,666 Fully Paid Ordinary Shares (AVE) 2. 2,499,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Pelehj145 Pty Ltd <M&L McNamara Super Fund> 1. 3,169,298 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Class Quoted options exercisable at $0.012 each expiring on 10 May 2026 (AVEOA) Number acquired Nil Number disposed 2,499,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil No. of securities held after change Indirect PELEHJ145 PTY LTD <M & L MCNAMARA SFA/C> 1. 1,666,666 Fully Paid Ordinary Shares (AVE) Pelehj145 Pty Ltd <M&L McNamara Super Fund> 1. 3,169,298 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Expiry of Quoted Options on 10 May 2026 Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? N/A If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity Avecho Biotechnology Limited ABN 32 056 482 403 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Ross Murdoch Date of last notice 27 May 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. N/A Date of change 10 May 2026 No. of securities held prior to change Direct 1. 3,333,333 Fully Paid Ordinary Shares (AVE) 2. 2,499,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) 3. 3,169,298 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Class Quoted options exercisable at $0.012 each expiring on 10 May 2026 (AVEOA) Number acquired Nil Number disposed 2,499,999 Quoted Options exercisable at $0.012 each and expiring on 10 May 2026 (AVEOA) Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation Nil Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 No. of securities held after change Direct 1. 3,333,333 Fully Paid Ordinary Shares (AVE) 2. 3,169,298 Unquoted Options exercisable at $0.0066 each and expiring on 27 November 2028 (AVEAS) Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Expiry of Quoted Options on 10 May 2026 Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? N/A If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A